XML 23 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:        
Net loss $ (1,092,088) $ (17,366,866) $ (38,043,362) $ (32,357,957)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 1,765,619 1,113,188 1,653,819 862,888
Amortization of loan discount and fees 1,611,433 2,818,174 6,506,384 1,382,222
Loss on extinguishment of debt 689,100      
Loss on disposition of business 1,523,940      
Stock-based compensation 207,094 258,852 602,038 4,800,337
Shares issued for services 499,338      
Accounts Receivable, Credit Loss Expense (Reversal)     (118,840) 36,893
Change in credit reserve 344,140 (5,053)    
Change in fair value of contingent consideration (10,698,475) 7,121,240 564,303 8,764,460
Discontinued operations 7,666      
Fees incurred in connection with debt financings     568,149 560,309
Change in fair value of warrant liability   (18,223) (18,223) 11,958
Change in fair value of derivative liability   (880,388) (1,354,434) (910,204)
Forgiveness of Payroll Protection Program   (1,760,755) (1,760,755) (407,994)
Deferred offering costs     367,696  
Deferred income tax benefit       (1,100,120)
Changes in operating assets and liabilities:        
Accounts receivable, net 375,685 (100,662) (452,030) 150,288
Due from factor, net (96,955) 202,787 655,708 (399,701)
Inventory 454,011 (128,255) 479,394 (911,293)
Prepaid expenses and other current assets (44,213) (395,781) (445,798) (151,917)
Accounts payable 92,494 435,110 892,120 456,690
Accrued expenses and other liabilities 1,346,068 1,461,572 1,631,512 834,489
Deferred revenue (183,782) (55,034)   4,882
Due to related parties     298,943 (63,550)
Accrued interest 217,479 690,624 984,358 461,113
Net cash used in operating activities (2,981,446) (6,609,470) (10,767,706) (14,230,957)
Cash flows from investing activities:        
Cash acquired (consideration) pursuant to business combination     (7,247,303) (5,936,757)
Deposits (18,192)   (60,548) (31,117)
Purchase of property, equipment and software (27,855)   (61,286) (43,179)
Deposits 87,378      
Net cash provided by (used in) investing activities 41,331   (7,369,137) (6,011,053)
Cash flows from financing activities:        
Proceeds (repayments) from related party advances (57,427) (172,036)    
Advances (repayments) from factor 154,073 (142,436) (3,096) (41,200)
Repayment of contingent consideration     (645,304)  
Issuance of loans and note payable 4,194,799 548,808    
Repayments of convertible notes and loans payable (6,604,552) (3,068,750) (7,350,276) (2,006,628)
Issuance of convertible notes payable   2,301,250 6,951,250 8,433,650
Issuance of common stock in public offering 5,000,003 9,347,450 19,347,446 10,000,002
Exercise of over-allotment option with public offering, net       (1,364,997)
Exercise of warrants       1,768,046
Offering costs (686,927) (1,930,486) (2,921,216) (2,116,957)
Net cash provided by financing activities 1,999,969 6,883,800 18,896,664 20,181,820
Net change in cash and cash equivalents (940,146) 274,330 759,820 (60,190)
Cash and cash equivalents at beginning of period 1,275,616 515,796 515,796 575,986
Cash and cash equivalents at end of period 335,470 802,724 1,275,616 515,796
Supplemental disclosure of cash flow information:        
Cash paid for interest 686,071 191,152 734,869 902,089
Supplemental disclosure of non-cash investing and financing activities:        
Conversion of notes into common stock   1,802,372 11,983,389 2,680,289
Conversion of notes into preferred stock 5,759,177      
Right of use asset $ 467,738 201,681 102,349  
Warrant and common shares issued with notes.   $ 98,241 1,368,741  
Conversion of venture debt into preferred stock     $ 6,300,000  
Conversion of related party notes and payables into preferred and common stock       257,515
Conversion of preferred stock into common stock       6,291
Conversion of contingent consideration into common stock       73,500
Common shares issued pursuant to equity line of credit       $ 367,696